Commerce Bank Acquires New Holdings in Qiagen N.V. (QGEN)
Commerce Bank acquired a new position in Qiagen N.V. (NASDAQ:QGEN) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 8,400 shares of the company’s stock, valued at approximately $282,000.
A number of other large investors have also modified their holdings of QGEN. BlackRock Inc. lifted its position in Qiagen N.V. by 8,793.4% during the 1st quarter. BlackRock Inc. now owns 7,839,636 shares of the company’s stock worth $227,114,000 after acquiring an additional 7,751,485 shares during the last quarter. Legal & General Group Plc lifted its position in Qiagen N.V. by 2,651.3% during the 1st quarter. Legal & General Group Plc now owns 1,896,813 shares of the company’s stock worth $16,690,000 after acquiring an additional 1,827,871 shares during the last quarter. Edmond DE Rothschild Holding S.A. acquired a new position in Qiagen N.V. during the 1st quarter worth $46,480,000. Neuberger Berman Group LLC acquired a new position in Qiagen N.V. during the 1st quarter worth $31,875,000. Finally, Renaissance Technologies LLC lifted its position in Qiagen N.V. by 182.9% during the 1st quarter. Renaissance Technologies LLC now owns 1,514,898 shares of the company’s stock worth $43,890,000 after acquiring an additional 979,498 shares during the last quarter. Hedge funds and other institutional investors own 63.01% of the company’s stock.
WARNING: This report was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/09/12/commerce-bank-acquires-new-holdings-in-qiagen-n-v-qgen.html.
Qiagen N.V. (NASDAQ QGEN) opened at 32.20 on Tuesday. The firm has a market cap of $7.35 billion, a price-to-earnings ratio of 98.47 and a beta of 1.15. Qiagen N.V. has a 12 month low of $24.86 and a 12 month high of $35.26. The stock’s 50 day moving average is $32.17 and its 200-day moving average is $31.61.
Qiagen N.V. (NASDAQ:QGEN) last announced its earnings results on Thursday, July 27th. The company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.28 by $0.02. The business had revenue of $349 million during the quarter, compared to the consensus estimate of $353.09 million. Qiagen N.V. had a net margin of 5.44% and a return on equity of 11.04%. Qiagen N.V.’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.24 EPS. On average, analysts anticipate that Qiagen N.V. will post $1.20 earnings per share for the current fiscal year.
A number of research analysts have weighed in on QGEN shares. Commerzbank Ag reissued a “buy” rating on shares of Qiagen N.V. in a research report on Monday, May 15th. Barclays PLC reissued a “buy” rating and set a $33.00 target price on shares of Qiagen N.V. in a research report on Monday, May 15th. DZ Bank AG reissued a “neutral” rating on shares of Qiagen N.V. in a research report on Monday, May 15th. TheStreet raised shares of Qiagen N.V. from a “c” rating to a “b” rating in a research report on Monday, June 5th. Finally, BidaskClub lowered shares of Qiagen N.V. from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 10th. Nine analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $33.17.
About Qiagen N.V.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen N.V. (NASDAQ:QGEN).
Receive News & Stock Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related stocks with our FREE daily email newsletter.